Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | Evaluating the mechanism of action of emavusertib

Bently Doonan, MD, University of Florida, Gainesville, FL, gives an overview of how emavusertib (CA-4948) can treat melanoma brain metastases. Emavusertib is an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), which decreases cancer proliferation vis decreased expression of NF-κB. The investigatory drug can also target brain metastases as it can pass the blood-brain barrier and has proven to be safe in patients with leukemia and lymphoma. Further research has indicated tumor regression is feasible with the addition of anti-PD-1 checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.